logo

Galmed Pharmaceuticals Ltd. (GLMD)



Trade GLMD now with
  Date
  Headline
8/4/2022 8:14:01 AM Galmed Pharma Q2 Net Loss $3.7 Mln Or $0.15/shr Vs Net Loss Of $8.4 Mln Or $0.33/shr Prior Year
7/7/2022 8:34:41 AM Galmed Pharma Announces Significant Anti-Fibrotic Effects Of Aramchol In Lung Fibrosis Model
5/17/2022 8:15:41 AM Galmed Pharma Q1 Net Loss $6.1 Mln Or $0.24/shr Vs Net Loss Of $8.9 Mln Or $0.38/shr Prior Year
5/17/2022 7:49:16 AM Galmed : Data Reinforce Anti-fibrotic Activity Of Aramchol Previously Observed In Wide Range Of Pre-clinical Models
1/10/2022 7:33:10 AM Galmed Announces Positive Results Of Phase 1 Study Of Amilo-5MER In Healthy Volunteers
11/8/2021 7:34:01 AM Galmed Pharma Q3 Loss/shr Narrows To $0.31 From $0.32 Prior Year
11/8/2021 7:18:00 AM Galmed Announces New Positive Data From Open-Label Part Of The ARMOR Phase 3 Study
11/1/2021 10:18:24 AM Galmed Announces Positive Results From First 16 Patients In Open-Label Part Of ARMOR Study On NASH
10/11/2021 8:29:04 AM Galmed : Results Of Phase 2b ARREST Trial Of Aramchol Published In Nature Medicine
8/19/2021 8:07:55 AM Galmed Says Amilo-5MER Suppresses Chronic Inflammations In Broad Spectrum Of Animal Models Of Inflammatory Diseases
8/16/2021 8:12:45 AM MHRA Agrees With Galmed's Plan To Use Aramchol Meglumine In Phase 3 ARMOR Study